{
    "eid": "2-s2.0-85118498186",
    "title": "Lactic acidosis, a potential toxicity from drug\u2013drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report",
    "cover-date": "2022-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "concomitant",
        "drug\u2013drug interaction",
        "lactic acidosis",
        "renal insufficiency"
    ],
    "authors": [
        "Chalita Lagampan",
        "Nattaya Poovorawan",
        "Napa Parinyanitikul"
    ],
    "citedby-count": 0,
    "ref-count": 20,
    "ref-list": [
        "CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis",
        "Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future",
        "Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials",
        "Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3",
        "Overall survival with ribociclib plus fulvestrant in advanced breast cancer",
        "Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication",
        "Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017",
        "Transporters and drug-drug interactions: important determinants of drug disposition and effects",
        "Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer",
        "Membrane transporters in drug development",
        "Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report",
        "MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy",
        "Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate",
        "Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions",
        "Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer",
        "Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2\u2212 advanced breast cancer in the randomized MONALEESA-2 trial",
        "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial",
        "Metformin pathways: pharmacokinetics and pharmacodynamics",
        "The management of metformin overdose",
        "Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60002620",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
        "affiliation-country": "Thailand"
    },
    "funding": []
}